Roche Diagnostics Deepens China Commitment with $180 Million Additional Investment

SuzhouMay 15, 2020 /PRNewswire/ -- Recently, Roche announced that it would further increase its investment in the Roche Diagnostics Asia Pacific Production Base and R&D Center located in Suzhou Industrial Park. The proposed additional investment totals USD 180 million, bringing the cumulative total investment to USD 479 million. This capital injection will further deepen Roche Diagnostics' strategic layout in China and reaffirm its long-term commitment to being rooted in China, dedicated to growing alongside China's healthcare industry, and benefiting patients in China and across the Asia-Pacific region.

The new investment will be used for the construction of production facilities and product line transfer projects for various in vitro diagnostic reagents, including reagents for tissue diagnostic staining platforms and specialized diagnostic reagents.

As a global leader in the field of in vitro diagnostics, Roche Diagnostics is committed to providing advanced diagnostic solutions for patients, hospitals, and laboratories worldwide. In the fight against the global COVID-19 pandemic, Roche Diagnostics responded rapidly by developing and offering the cobas SARS-CoV-2 qualitative nucleic acid test.^[1]and Elecsys^®Anti-SARS-CoV-2 Antibody Test^[2]. In the future, Roche Diagnostics’ Asia-Pacific production base and R&D center are also expected to play a significant role in combating the global COVID-19 pandemic by manufacturing and supplying diagnostic products for China and other countries in the Asia-Pacific region.

China is one of the key strategic priorities for the Roche Group globally. Roche Diagnostics has always upheld its long-term commitment to the Chinese market, supporting the development of China’s healthcare industry by providing innovative and precise diagnostic products to Chinese patients, thereby contributing to the construction of a "Healthy China." This new investment will further help Roche Diagnostics deepen its strategic layout in China, enhance its market responsiveness, and bring high-quality diagnostic products across broader fields to China and even the Asia-Pacific region. In the future, Roche Diagnostics will continue to explore more opportunities for project implementation in China and actively participate in medical innovation projects with various stakeholders, aiming to introduce more cutting-edge in vitro diagnostic solutions to benefit Chinese patients.

Remarks:
[1] Under registration in China
[2] Currently under registration in China